High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models.
Liver metastasis is the main cause of colon cancer-related death and is a recalcitrant disease. We report here the efficacy and safety of intra-portal-vein (iPV) targeting of Salmonella typhimurium A1-R on colon cancer liver metastasis in a nude-mouse orthotopic model. Nude mice with HT29 human colon cancer cells, expressing red fluorescent protein (RFP) (HT29-RFP), growing in the liver were administered S. typhimurium A1-R by either iPV (1×104 colony forming units (CFU)/100 μl) or, for comparison, intra-venous injection (iv; 5×107 CFU/100 μl). Similar amounts of bacteria were delivered to the liver with the two doses, indicating that iPV delivery is 5×103 times more efficient than iv delivery. Treatment efficacy was evaluated by tumor fluorescent area (mm2) and total fluorescence intensity. Tumor fluorescent area and fluorescence intensity highly correlated (p<0.0001). iPV treatment was more effective compared to both untreated control and iv treatment (p<0.01 and p<0.05, respectively with iPV treatment with S. typhimurium arresting metastatic growth). There were no significant differences in body weight between all groups. The results of this study suggest that S. typhimurium A1-R administered iPV has potential for peri-operative adjuvant treatment of colon cancer liver metastasis.
AntiCancer, Inc., San Diego, California, USA.|Department of Surgery, University of California San Diego, San Diego, California, USA.|Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Kei
K
Kawaguchi
AntiCancer, Inc., San Diego, California, USA.
Takashi
T
Murakami
AntiCancer, Inc., San Diego, California, USA.
Atsushi
A
Suetsugu
AntiCancer, Inc., San Diego, California, USA.
Tasuku
T
Kiyuna
AntiCancer, Inc., San Diego, California, USA.
Kentaro
K
Igarashi
AntiCancer, Inc., San Diego, California, USA.
Yukihiko
Y
Hiroshima
AntiCancer, Inc., San Diego, California, USA.
Ming
M
Zhao
AntiCancer, Inc., San Diego, California, USA.
Yong
Y
Zhang
Department of Surgery, University of California San Diego, San Diego, California, USA.
Michael
M
Bouvet
Department of Surgery, University of California San Diego, San Diego, California, USA.
Bryan M
BM
Clary
Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Michiaki
M
Unno
AntiCancer, Inc., San Diego, California, USA.|Department of Surgery, University of California San Diego, San Diego, California, USA.
Robert M
RM
Hoffman
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000473:pathology*; D019073:HT29 Cells; D006801:Humans; D007275:Injections, Intravenous; D008113:Liver Neoplasms / Q000556:secondary*; D051379:Mice; D008819:Mice, Nude; D011169:Portal Vein; D012481:Salmonella Infections, Animal; D012486:Salmonella typhimurium; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents
Salmonella typhimurium A1-R; liver metastasis; nude mice; orthotopic; tumor targeting
Nat Protoc. 2006;1(2):775-82
17406307
J Clin Oncol. 1990 Sep;8(9):1466-75
2202789
Oncotarget. 2016 Jul 26;7(30):47556-47564
27286459
Anticancer Res. 2009 Jun;29(6):1873-8
19528442
Cell Cycle. 2010 Nov 15;9(22):4518-24
21135579
Drug Discov Today. 2003 Dec 15;8(24):1104-7
14678733
Oncotarget. 2015 May 10;6(13):11369-77
25957417
Nat Protoc. 2006;1(3):1429-38
17406431
Oncotarget. 2015 Feb 20;6(5):2615-22
25575815
Lancet. 1995 Feb 11;345(8946):349-53
7845115
Oncotarget. 2015 Jun 10;6(16):14625-31
25714030
Ann Surg. 2016 Mar;263(3):434-9
26465781
Cancer Res. 2006 Aug 1;66(15):7647-52
16885365
Cell Cycle. 2009 Mar 15;8(6):870-5
19221501
J Cell Biochem. 2011 Aug;112(8):2046-50
21465525
Cell Cycle. 2005 Nov;4(11):1518-21
16258270
J Cell Biochem. 2014 Nov;115(11):1996-2003
24924355
Br J Surg. 1985 May;72(5):359-63
3888335
J Cell Biochem. 2017 Feb;118(2):361-365
27357060
J Surg Res. 2010 Dec;164(2):248-55
19766244
Cancer Res. 2006 Apr 15;66(8):4208-14
16618743
Anticancer Res. 2012 Oct;32(10):4331-7
23060555
PLoS One. 2015 Aug 03;10(8):e0134324
26237416
PLoS One. 2016 Aug 08;11(8):e0160882
27500926
Ann Oncol. 2005;16 Suppl 2:ii144-9
15958446
Cell Cycle. 2014;13(24):3958-63
25483077
J Cell Biochem. 2014 Jul;115(7):1254-61
24435915
Oncotarget. 2016 May 31;7(22):33046-54
27105519
Oncotarget. 2011 Mar;2(3):222-33
21447859
Nat Protoc. 2006;1(2):928-35
17406326
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60
15644448
Leukemia. 2006 Mar;20(3):385-91
16357832
Oncotarget. 2016 Mar 15;7(11):12783-90
26859573
Anticancer Res. 2012 Jul;32(7):2501-8
22753706
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10170-4
17548809
Ann Surg. 1957 Oct;146(4):588-93; discussion 593-5
13470750
J Cell Biochem. 2009 Apr 15;106(6):992-8
19199339
PLoS One. 2015 Jun 05;10(6):e0120358
26047477
Drug Discov Ther. 2014 Oct;8(5):194-200
25382553
Oncotarget. 2014 Dec 30;5(24):12849-61
25528763
Clin Cancer Res. 2000 Jun;6(6):2464-8
10873100
Oncotarget. 2014 Dec 15;5(23):12346-57
25402324
Leukemia. 2001 Jun;15(6):936-41
11417480
Cell Cycle. 2013 Sep 1;12(17):2774-80
23966167
Ann Surg. 2009 Sep;250(3):440-8
19730175
Oncotarget. 2015 Dec 8;6(39):41856-62
26497690
Sci Transl Med. 2014 Aug 13;6(249):249ra111
25122639
Cell Cycle. 2012 Feb 1;11(3):628-32
22274398